Structures Facilitate On-site Immediate Coronavirus Testing
SG Blocks, Inc. (NASDAQ: SGBX), a leading designer, innovator and fabricator of container-based structures, today announced the D-Tec suite of prefabricated health facilities created in partnership with Grimshaw and OSANG Healthcare for on-site immediate COVID-19 testing. The D-Tec suite is designed to meet an urgent global demand for safe, easily deployable medical response solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005231/en/
Example of a modular shipping container repurposed as walk-in medical clinic (Photo: Business Wire)
This deployable technology line upcycles disused shipping containers as a foundation for a sturdy and sustainable solution to mass testing needs. Its design offers a safe, efficient environment for testing collection and onsite deployable laboratory analysis.
Paul Galvin, Chairman and CEO of SG Blocks, Inc. commented "Grimshaw’s commitment to human centric design combined with OSANG’s extremely accurate tests should enable SG Blocks to create turnkey testing facilities throughout the USA to provide access to the greatest number of people without compromising the needs of staff or users. We can think of no better partners to help supplement the existing health care system."
Andrew Whalley, Grimshaw chairman states "Grimshaw recognizes the important role that a rapidly deployable solution has in opening up greater access to testing that people can trust and rely on. We have always aimed to deliver progressive architecture that strives for a better future, and we believe this suite of highly adaptable, efficient building solutions developed by our Industrial Design team will provide greater opportunities for the critical role testing, and people’s trust in testing sites, will play as we move forward."
Dong-Hyun Lee, Chairman & Chief Executive Officer of OSANG Healthcare Co., Ltd. stated, "We view SG Blocks and Grimshaw as ideal partners to broaden distribution of our advanced tests and expand our ability to directly address this global pandemic in the USA. Our pipeline is substantial, we believe Grimshaw’s commitment to sustainable, flexible design solutions combined with SG Blocks modular construction expertise has the ability to address logistical challenges."
The first prototypes, slated for completion in June, will offer ample space for social distancing, access to hand-washing stations and a purified air system so medical professionals and patients can be confident their health and well-being is protected throughout their visit. Other features will include physical separation between medical staff and patients, contact-less testing, walk-up windows, and rapid, on-site sample processing.
About SG Blocks, Inc.
SG Blocks, Inc. is a premier innovator in advancing and promoting the use of code-engineered cargo shipping containers for safe and sustainable construction. The firm offers a product that exceeds many standard building code requirements, and also supports developers, architects, builders and owners in achieving greener construction, faster execution, and stronger buildings of higher value. Each project starts with GreenSteel™, the structural core and shell of an SG Blocks building, and then customized to client specifications. For more information, visit www.sgblocks.com.
Grimshaw was founded by Sir Nicholas Grimshaw in 1980. The practice operates worldwide, across all major sectors, with offices in London, Paris, New York, Los Angeles, Dubai, Melbourne and Sydney, employing over 650 staff. Grimshaw has been honoured with over 200 awards for its commitment to excellence and innovation, including ‘Practice of the Year’ and ‘Building of the Year’ at the 2019 AJ100. In 2019, Founder Sir Nicholas Grimshaw was awarded the Royal Gold Medal for Architecture by the Royal Institute of British Architects.
About OSANG Healthcare Co., Ltd.
OSANG Healthcare is a South Korea based global manufacturer and distributor of medical devices and in-vitro diagnostics solutions. Devoted since inception to the development of diagnostic biosensors for blood glucose measurement, OSANG Healthcare envisions medical devices becoming as commonplace as home appliances, easily measuring all diseases across the globe as "Technology for Human". OSANG Healthcare currently exports its diagnostic biosensors for blood glucose, HbA1c and cholesterol to more than 110 countries, in its drive to become the leading researcher and developer of diagnostic sensors for heart disease and cancer, and of remote diagnosis systems. For more information, visit www.osanghc.com.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding creating turnkey testing facilities throughout the USA to provide access to the greatest number of people without compromising the needs of staff or users, the suite of building solutions developed by Grimshaw’s Industrial Design team providing greater opportunities for the critical role testing, and people’s trust in testing sites, will play in the future, Grimshaw’s commitment to sustainable, flexible design solutions combined with SG Blocks modular construction expertise having the ability to address logistical challenges and the first prototypes being slated for completion in June. While SG Blocks believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to create turnkey testing facilities throughout the USA to provide access to the greatest number of people without compromising the needs of staff or users, the ability of the suite of building solutions developed by Grimshaw’s Industrial Design team to provide greater opportunities for the critical role testing, and people’s trust in testing sites, will play in the future, the Company’s and Grimshaw’s ability to complete the first prototypes slated for completion in June and address logistical challenges, the Company’s ability to position itself for future profitability, the Company’s ability to maintain compliance with the NASDAQ listing requirements, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Rubenstein Public Relations